The use of B-cell targeted therapies for the treatment of systemic lupus erythematosus (SLE) has generated great interest owing to the multiple pathogenic roles carried out by B cells in this disease.

pDCs are considered the primary source of IFN-α, which, as will be discussed below, makes them potentially very relevant to the immunopathology of SLE ... control B-cell proliferation ...